CN106581031A - Compound Western medicine for treating pertussis - Google Patents
Compound Western medicine for treating pertussis Download PDFInfo
- Publication number
- CN106581031A CN106581031A CN201611171973.7A CN201611171973A CN106581031A CN 106581031 A CN106581031 A CN 106581031A CN 201611171973 A CN201611171973 A CN 201611171973A CN 106581031 A CN106581031 A CN 106581031A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- pertussal
- compound western
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a compound Western medicine for treating pertussis. The compound Western medicine is prepared from the following main raw materials in parts by weight: 5-15 parts of camellianin A, 3-7 parts of palmatrubine, 20-30 parts of norswertianolin, 8-12 parts of taccalonolide B, 2-4 parts of ginkgetin, 1-3 parts of isomangiferin, 10-15 parts of menthol, 23-30 parts of campesterol, 2-5 parts of 5-hydroxy-p-naphthoquinone, and 2-4 parts of sanguinarine citrate. According to the compound Western medicine, the raw materials are strictly selected according to the knowing mechanism for pertussis, so that the purpose of comprehensive rehabilitation is achieved, and in addition, the compound Western medicine has the advantages of being rapid in taking effect, stable in effect, convenient to carry and take, and free of toxic and side effects after long-term administration.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically one kind treat pertussal compound Western medicine.
Background technology
Pertussis are the common Acute respiratory infectious diseases of children, and bordetella pertussis are the pathogenic bacterium of primary disease.It is characterized by
Paroxysmal spasmodic cough, cough end is with special air-breathing roar, and the course of disease is longer, up to even 3 months or so several weeks, therefore has
The title of pertussis.Baby tends to have the complication such as asphyxia, pneumonia, encephalopathy when suffering from primary disease, case fatality rate is high.Baby and into Crinis Carbonisatus in recent years
Disease has and increases trend, and 40% is the infant within 5 months in death.Antibiotic therapy is applied early, and general prognosis is good
It is good.The sick various places all over the world, typically in shape is distributed, can happening and prevelence in child's collection body mechanism.Whole year can fall ill, with the winter
Spring is many, can be extended down to the end of spring and the beginning of summer, or even peak in 6,7,8 three month.Patient and Asympto matic carrier are the sources of infection,
All it was infectious by the 6th week from incubation period, by droplet transmission.Crowd is universal to the disease susceptible, about 2/3 case be 7 years old with
Lower children are especially more with less than 5 years old person.This is that specific antibody due to obtaining from parent because of infant is few, the most susceptible.It is little
Youngster tends to have the complication such as asphyxia, pneumonia, encephalopathy when suffering from primary disease, case fatality rate is high, and serious threat child's is healthy.At present, face
The general patient of pertussis is treated on bed using antibiotic medicines such as Luo Hongsu, Sulfamethoxazole Compounds, can short-term to critical patient
Using Adrenal Glucocorticoid.Though said medicine treatment pertussis have certain curative effect, side effect is very big.
The content of the invention
It is an object of the invention to provide one kind treats pertussal compound Western medicine, to solve above-mentioned background technology in propose
Problem.
For achieving the above object, the present invention provides following technical scheme：
One kind treats pertussal compound Western medicine, is according to the primary raw material of weight portion：Camellianin A 5-15 parts, palmatine
Red alkali 3-7 parts, demethylbellidifolin FMDV VP1 gene 20-30 parts, Tacca chantrieri ketone lactone B 8-12 parts, ginkegetin 2-4
Part, Isomangiferin 1-3 parts, menthol 10-15 parts, campesterol 23-30 parts, 5- hydroxyls are to naphthoquinone 2-5 parts, sanguinarine citrate
2-4 parts.
As further scheme of the invention：It is described to treat pertussal compound Western medicine, according to the primary raw material of weight portion
For：Camellianin A 8-12 parts, the red alkali 4-6 parts of palmatine, demethylbellidifolin FMDV VP1 gene 22-26 parts, in Tacca chantrieri ketone
Ester B 9-11 parts, ginkegetin 2-4 parts, Isomangiferin 1-3 parts, menthol 12-14 parts, campesterol 25-27 parts, 5- hydroxyls
To naphthoquinone 2-5 parts, sanguinarine citrate 2-4 parts.
As further scheme of the invention：It is described to treat pertussal compound Western medicine, according to the primary raw material of weight portion
For：5 parts of the red alkali of 10 parts of camellianin A, palmatine, 24 parts of demethylbellidifolin FMDV VP1 gene, Tacca chantrieri ketone lactone B 10
Part, 3 parts of ginkegetin, 2 parts of Isomangiferin, 13 parts of menthol, 26 parts of campesterol, 5- hydroxyls are to 4 parts of naphthoquinone, citron acidemia
3 parts of root alkali.
A kind of preparation method for treating pertussal compound Western medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, the red alkali of camellianin A, palmatine, demethyl Bellis perennis leaf are weighed by above-mentioned metering ratio
Gentisin glycosides, Tacca chantrieri ketone lactone B, ginkegetin, Isomangiferin, menthol, campesterol, 5- hydroxyls to naphthoquinone,
Sanguinarine citrate, sieves, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing 4-8min, control RSD≤
5%, tabletting and cold drying after mixing, at 4-8 DEG C, packaging obtains final product the pertussal compound Western medicine for the treatment of to temperature control.
As further scheme of the invention：Mix 6min in concrete steps.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention is strictly selected material composition according to pertussal understanding mechanism, so as to reach comprehensive rehabilitation
Purpose, with rapid-action, effect it is stable, carry taking convenience, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
One kind treats pertussal compound Western medicine, is according to the primary raw material of weight portion：5 parts of camellianin A, palmatine are red
3 parts of alkali, 20 parts of demethylbellidifolin FMDV VP1 gene, 8 parts of Tacca chantrieri ketone lactone B, 2 parts of ginkegetin, Isomangiferin 1
Part, 10 parts of menthol, 23 parts of campesterol, 5- hydroxyls are to 2 parts of naphthoquinone, 2 parts of sanguinarine citrate.
A kind of preparation method for treating pertussal compound Western medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, the red alkali of camellianin A, palmatine, demethyl Bellis perennis leaf are weighed by above-mentioned metering ratio
Gentisin glycosides, Tacca chantrieri ketone lactone B, ginkegetin, Isomangiferin, menthol, campesterol, 5- hydroxyls to naphthoquinone,
Sanguinarine citrate, sieves, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing 4min, control RSD≤
5%, tabletting and cold drying after mixing, at 4 DEG C, packaging obtains final product the pertussal compound Western medicine for the treatment of to temperature control.
Embodiment 2
One kind treats pertussal compound Western medicine, is according to the primary raw material of weight portion：8 parts of camellianin A, palmatine are red
4 parts of alkali, 22 parts of demethylbellidifolin FMDV VP1 gene, 9 parts of Tacca chantrieri ketone lactone B, 2 parts of ginkegetin, Isomangiferin 1
Part, 12 parts of menthol, 25 parts of campesterol, 5- hydroxyls are to 2 parts of naphthoquinone, 2 parts of sanguinarine citrate.
A kind of preparation method for treating pertussal compound Western medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, the red alkali of camellianin A, palmatine, demethyl Bellis perennis leaf are weighed by above-mentioned metering ratio
Gentisin glycosides, Tacca chantrieri ketone lactone B, ginkegetin, Isomangiferin, menthol, campesterol, 5- hydroxyls to naphthoquinone,
Sanguinarine citrate, sieves, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing 4min, control RSD≤
5%, tabletting and cold drying after mixing, at 4 DEG C, packaging obtains final product the pertussal compound Western medicine for the treatment of to temperature control.
Embodiment 3
One kind treats pertussal compound Western medicine, is according to the primary raw material of weight portion：10 parts of camellianin A, palmatine are red
5 parts of alkali, 24 parts of demethylbellidifolin FMDV VP1 gene, 10 parts of Tacca chantrieri ketone lactone B, 3 parts of ginkegetin, Isomangiferin 2
Part, 13 parts of menthol, 26 parts of campesterol, 5- hydroxyls are to 4 parts of naphthoquinone, 3 parts of sanguinarine citrate.
A kind of preparation method for treating pertussal compound Western medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, the red alkali of camellianin A, palmatine, demethyl Bellis perennis leaf are weighed by above-mentioned metering ratio
Gentisin glycosides, Tacca chantrieri ketone lactone B, ginkegetin, Isomangiferin, menthol, campesterol, 5- hydroxyls to naphthoquinone,
Sanguinarine citrate, sieves, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing 6min, control RSD≤
5%, tabletting and cold drying after mixing, at 6 DEG C, packaging obtains final product the pertussal compound Western medicine for the treatment of to temperature control.
Embodiment 4
One kind treats pertussal compound Western medicine, is according to the primary raw material of weight portion：12 parts of camellianin A, palmatine are red
6 parts of alkali, 26 parts of demethylbellidifolin FMDV VP1 gene, 11 parts of Tacca chantrieri ketone lactone B, 4 parts of ginkegetin, Isomangiferin 3
Part, 14 parts of menthol, 27 parts of campesterol, 5- hydroxyls are to 5 parts of naphthoquinone, 4 parts of sanguinarine citrate.
A kind of preparation method for treating pertussal compound Western medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, the red alkali of camellianin A, palmatine, demethyl Bellis perennis leaf are weighed by above-mentioned metering ratio
Gentisin glycosides, Tacca chantrieri ketone lactone B, ginkegetin, Isomangiferin, menthol, campesterol, 5- hydroxyls to naphthoquinone,
Sanguinarine citrate, sieves, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing 8min, control RSD≤
5%, tabletting and cold drying after mixing, at 8 DEG C, packaging obtains final product the pertussal compound Western medicine for the treatment of to temperature control.
Embodiment 5
One kind treats pertussal compound Western medicine, is according to the primary raw material of weight portion：15 parts of camellianin A, palmatine are red
7 parts of alkali, 30 parts of demethylbellidifolin FMDV VP1 gene, 12 parts of Tacca chantrieri ketone lactone B, 4 parts of ginkegetin, Isomangiferin 3
Part, 15 parts of menthol, 30 parts of campesterol, 5- hydroxyls are to 5 parts of naphthoquinone, 4 parts of sanguinarine citrate.
A kind of preparation method for treating pertussal compound Western medicine, concretely comprises the following steps：
First, in pharmaceutical grade clean area, the red alkali of camellianin A, palmatine, demethyl Bellis perennis leaf are weighed by above-mentioned metering ratio
Gentisin glycosides, Tacca chantrieri ketone lactone B, ginkegetin, Isomangiferin, menthol, campesterol, 5- hydroxyls to naphthoquinone,
Sanguinarine citrate, sieves, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing 4-8min, control RSD≤
5%, tabletting and cold drying after mixing, at 8 DEG C, packaging obtains final product the pertussal compound Western medicine for the treatment of to temperature control.
Pharmacology test
1st, chronic toxicity test
With compound Western medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, successive administration 2 in 24h
It is secondary, per minor tick 8h, 100mg/kg doses are administered every time, daily accumulation medicine total amount reaches 200mg medicines/kg, faces equivalent to people
100 times of bed consumption.After administration in 7d, mice activity, feed, excretion are normal, well-grown, hair color light, its average body
Weight increases with the prolongation of experimental period.Every mice of post mortem at 8d, the perusal heart, liver, spleen, lung, kidney, brain,
Thymus, stomach, intestinal etc. do not find color and paramophia, fail to measure median lethal dose(LD 50) (LD50).As a result show：The present invention is multiple
Western medicine is closed without chronic toxicity.
2nd, long term toxicity test
With compound Western medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, by the compound Western medicine of the present invention
Be divided into low dosage, middle dosage, three groups of high dose, the drug dose of each group is respectively 20,40,60mg medicines/kg/d, equivalent to facing
10,20,30 times of bed dosage.After gastric infusion 24 weeks, general status, hematological indices, blood of the medicine of the present invention to animal
Biochemical indicator without significantly impact, Systematic anatomy, organ coefficient and histopathological examination also no abnormal pathological change.
It is discontinued 2 weeks and also has no substantially change.As a result show：The compound Western medicine of the present invention does not find overt toxicity in long term toxicity test
Reaction and delayed toxicity reaction.It can be seen that, the compound Western medicine non-toxic reaction of the present invention, long-term prescription is safe and reliable.
3rd, clinical trial
Accept outpatient service infant 141 for medical treatment, daily dose is 2mg/kg, is within 3 days a course for the treatment of.
Diagnostic criteria：Children whooping cough their early stage is such as influenza, it may appear that watery nasal discharge, sneeze, low grade fever, symptom of tussiculaing, its
Coughs in two weeks afterwards gradually aggravate, and have violent apasm of coughing, and fierce cough constantly causes dyspnea.There are this feelings
The breathing of patient during condition is in typical crow sound.The baby of less than 6 months is normally not present typical crow.Detailed clinical is showed
Can be divided into for three phases：It is first catarrhal period, is showed only as the upper respiratory tract infection symptoms such as low grade fever, cough, watery nasal discharge, sneeze.7～10 days
After proceed to stage of spasmodic cough, show as paroxysmal pain contraction cough, outbreak increasingly sharpens, as long as each apasm of coughing is up to several minutes.After coughing
With a crow sample apneusis.If treatment is not good at, this phase is 2～6 weeks.It is finally convalescent period, apasm of coughing decrescence even stops,
2 weeks or longer this phase.If there is respiratory tract infection again to cause pain to cough.
Efficacy assessment standard：
It is effective：Children whooping cough symptom is controlled, and infant cough is reduced, and the state of an illness starts to recover.Take a turn for the better：Children whooping cough
Symptom is improved, and infant is uncomfortable to be mitigated, and cough no longer aggravates, and the state of an illness progressively takes a turn for the better.It is invalid：Improvement standard person is not reached.
Therapeutic outcome：After one course for the treatment of, 141 infants, 120 are effective, 18 improvements, 3 invalid, total effective rates
97.9%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of description is only that for clarity those skilled in the art should
Using description as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (5)
1. one kind treats pertussal compound Western medicine, it is characterised in that the primary raw material according to weight portion is：Camellianin A 5-15
Part, the red alkali 3-7 parts of palmatine, demethylbellidifolin FMDV VP1 gene 20-30 parts, Tacca chantrieri ketone lactone B 8-12 parts, Semen Ginkgo
Bisflavone 2-4 parts, Isomangiferin 1-3 parts, menthol 10-15 parts, campesterol 23-30 parts, 5- hydroxyls are to naphthoquinone 2-5 parts, Chinese holly
Rafter acid Sanguinarine 2-4 parts.
2. it is according to claim 1 to treat pertussal compound Western medicine, it is characterised in that the treatment is pertussal compound
Western medicine, be according to the primary raw material of weight portion：Camellianin A 8-12 parts, the red alkali 4-6 parts of palmatine, demethylbellidifolin mouth
Xanthone glycosides 22-26 parts, Tacca chantrieri ketone lactone B 9-11 parts, ginkegetin 2-4 parts, Isomangiferin 1-3 parts, menthol 12-14
Part, campesterol 25-27 parts, 5- hydroxyls are to naphthoquinone 2-5 parts, sanguinarine citrate 2-4 parts.
3. it is according to claim 1 and 2 to treat pertussal compound Western medicine, it is characterised in that the treatment is pertussal
Compound Western medicine, be according to the primary raw material of weight portion：5 parts of the red alkali of 10 parts of camellianin A, palmatine, demethylbellidifolin mouth
24 parts of xanthone glycosides, 10 parts of Tacca chantrieri ketone lactone B, 3 parts of ginkegetin, 2 parts of Isomangiferin, 13 parts of menthol, campesterol 26
Part, 5- hydroxyls are to 4 parts of naphthoquinone, 3 parts of sanguinarine citrate.
4. a kind of preparation method of the pertussal compound Western medicine for the treatment of as described in claim 1-3 is arbitrary, it is characterised in that tool
Body step is：
First, in pharmaceutical grade clean area, the red alkali of camellianin A, palmatine, demethylbellidifolin are weighed by above-mentioned metering ratio
FMDV VP1 gene, Tacca chantrieri ketone lactone B, ginkegetin, Isomangiferin, menthol, campesterol, 5- hydroxyls are to naphthoquinone, citron
Sour Sanguinarine, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4-8min, controls RSD≤5%,
Tabletting and cold drying after mixing, at 4-8 DEG C, packaging obtains final product the pertussal compound Western medicine for the treatment of to temperature control.
5. the preparation method of the pertussal compound Western medicine for the treatment of according to claim 4, it is characterised in that in concrete steps
Mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171973.7A CN106581031A (en) | 2016-12-17 | 2016-12-17 | Compound Western medicine for treating pertussis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171973.7A CN106581031A (en) | 2016-12-17 | 2016-12-17 | Compound Western medicine for treating pertussis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581031A true CN106581031A (en) | 2017-04-26 |
Family
ID=58601195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611171973.7A Withdrawn CN106581031A (en) | 2016-12-17 | 2016-12-17 | Compound Western medicine for treating pertussis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581031A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109674807A (en) * | 2019-01-18 | 2019-04-26 | 中国医学科学院阜外医院 | A kind of CSE zymoexciter and its with CSE/H2Application in the relevant disease medicament of S system |
-
2016
- 2016-12-17 CN CN201611171973.7A patent/CN106581031A/en not_active Withdrawn
Non-Patent Citations (4)
| Title |
|---|
| 丁安伟主编: "《现代中药临床手册》", 31 August 2000, 江苏科学技术出版社 * |
| 朱胤龙主编: "《实用临床中药学》", 31 July 2013, 陕西科学技术出版社 * |
| 杨卫平等: "《常用中草药图谱及配方1》", 30 September 2012, 贵阳科技出版社 * |
| 罗迎春: "《贵州民族常用天然药物 第2卷》", 30 April 2013, 贵州科技出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109674807A (en) * | 2019-01-18 | 2019-04-26 | 中国医学科学院阜外医院 | A kind of CSE zymoexciter and its with CSE/H2Application in the relevant disease medicament of S system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8394423B2 (en) | Compositions comprising apocynin, ginkgo and ginger and uses thereof | |
| CN106581031A (en) | Compound Western medicine for treating pertussis | |
| CN104800322A (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method of traditional Chinese medicine composition | |
| CN106474197A (en) | One kind treats pertussal combination drug | |
| CN106692294A (en) | Compound Chinese-Western combination for treating pertussis and preparation method thereof | |
| CN1660256A (en) | Medication for treating cough caused by inflammation of upper respiratory tract | |
| CN106728145A (en) | It is a kind of to treat Chinese and western medicinal composition of acute diarrhea and preparation method thereof | |
| CN106581274A (en) | Chinese and western medicine composite for treating amygdalitis and preparing method thereof | |
| CN106511440A (en) | Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof | |
| CN106727907A (en) | A kind of Chinese and Western medicine combination for treating viral pneumonia and preparation method thereof | |
| CN101104023A (en) | Traditional Chinese medicine for treating infant diaper rash | |
| CN106581025A (en) | Composite western medicine for treating chronic dysentery | |
| CN106581024A (en) | Western medicine composition for treating hyperlipidemia | |
| CN106668600A (en) | Composite preparation for treating chronic glomerulitis | |
| CN106822239A (en) | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof | |
| CN106511665A (en) | Pharmaceutical for treating allergic pneumonia | |
| CN106727642A (en) | A kind of children's antipyretic | |
| CN101152361A (en) | Traditional Chinese medicine for treating chronic simple rhinitis | |
| CN106668000A (en) | Medicine for treating asthmatic bronchitis | |
| CN106822133A (en) | A kind of Western medicine compound for treating acute diarrhea | |
| CN106581038A (en) | Asthma treatment medicine | |
| CN106692457A (en) | Medicine for treating viral pneumonia | |
| CN1814192A (en) | Medicine for treating infant's fever and cough and preparing method | |
| CN106581023A (en) | Western medicine for treating viral pneumonia | |
| CN106581005A (en) | Western medicinal composition for treating amygdalitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170426 |
|
| WW01 | Invention patent application withdrawn after publication |